Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1–risk myelodysplastic syndromes with karyotypes other than deletion 5q

Azra Raza, James A. Reeves, Eric J. Feldman, Gordon W. Dewald, John M. Bennett, H. Joachim Deeg, Luke Dreisbach, Charles A. Schiffer, Richard M. Stone, Peter L. Greenberg, Peter T. Curtin, Virginia M. Klimek, Jamile M. Shammo, Deborah Thomas, Robert D. Knight, Michele Schmidt, Kenton Wride, Jerome B. Zeldis, Alan F. List

Blood (2008) 111 (1): 86–93.

https://doi.org/10.1182/blood-2007-01-068833

Published: 2008

Includes: Supplemental data

Journal Articles

Lenalidomide Response in Relapsed/Refractory Aggressive Non-Hodgkin’s Lymphoma Is Related to Tumor Burden and Time from Rituximab Treatment.

Peter H. Wiernik, MD, Izidore S. Lossos, MD, Joseph M. Tuscano, MD, Glen Justice, MD, Julie M. Vose, MD, Craig E. Cole, MD, Kyle McBride, MS, Kenton Wride, Dennis Pietronigro, PhD, Kenichi Takeshita, MD, Annette Ervin-Haynes, DO, Jerome B. Zeldis, MD, PhD, Thomas M. Habermann, MD

Blood (2007) 110 (11): 2565.

https://doi.org/10.1182/blood.V110.11.2565.2565

Published: 2007

Journal Articles

Lenalidomide-Induced Cytopenias: Relationship to Hematologic Improvement in Patients with Myelodysplastic Syndromes (MDS).

Mikkael A. Sekeres, Jaroslaw P. Maciejewski, Aristoteles Giagounidis, Kenton Wride, Robert D. Knight, Azra Raza, Alan F. List

Blood (2007) 110 (11): 821.

https://doi.org/10.1182/blood.V110.11.821.821

Published: 2007

Journal Articles

Long Term Clinical Benefit of Lenalidomide (Revlimid) Treatment in Patients with Myelodysplastic Syndrome without Del 5q Cytogenetic Abnormalities.

Azra Raza, MD, James E. Reeves, MD, Eric J. Feldman, MD, H. Joachim Deeg, MD, Luke Dreisbach, MD, Charles A. Schiffer, MD, Jamile M. Shammo, MD, Virginia M. Klimek, MD, Peter L. Greenberg, MD, John M. Bennett, MD, Gordon W. DeWald, PhD, Jerome B. Zeldis, MD, PhD, Kenton Wride, MS, Michele Schmidt, RN,C, Robert D. Knight, MD, Alan F. List, MD

Blood (2006) 108 (11): 250.

https://doi.org/10.1182/blood.V108.11.250.250

Published: 2006

Journal Articles

Long-Term Clinical Benefit of Lenalidomide (Revlimid) Treatment in Patients with Myelodysplastic Syndrome and Chromosome Deletion 5q.

Alan F. List, MD, Gordon W. Dewald, PhD, John M. Bennett, MD, Aristoteles Giagounidis, MD, Azra Raza, MD, Eric J. Feldman, MD, Bayard L. Powell, MD, Peter L. Greenberg, MD, Stephen D. Nimer, MD, Jerome B. Zeldis, MD, PhD, Kenton Wride, MS, Michele Schmidt, RNC, Robert D. Knight, MD

Blood (2006) 108 (11): 251.

https://doi.org/10.1182/blood.V108.11.251.251

Published: 2006

Journal Articles

A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma

Blood (2006) 108 (10): 3458–3464.

https://doi.org/10.1182/blood-2006-04-015909

Published: 2006

NARROW

Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1–risk myelodysplastic syndromes with karyotypes other than deletion 5q

Lenalidomide Response in Relapsed/Refractory Aggressive Non-Hodgkin’s Lymphoma Is Related to Tumor Burden and Time from Rituximab Treatment.

Lenalidomide-Induced Cytopenias: Relationship to Hematologic Improvement in Patients with Myelodysplastic Syndromes (MDS).

Long Term Clinical Benefit of Lenalidomide (Revlimid) Treatment in Patients with Myelodysplastic Syndrome without Del 5q Cytogenetic Abnormalities.

Long-Term Clinical Benefit of Lenalidomide (Revlimid) Treatment in Patients with Myelodysplastic Syndrome and Chromosome Deletion 5q.

A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma

Email alerts

ASH Publications

American Society of Hematology

Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1–risk myelodysplastic syndromes with karyotypes other than deletion 5q

Lenalidomide Response in Relapsed/Refractory Aggressive Non-Hodgkin’s Lymphoma Is Related to Tumor Burden and Time from Rituximab Treatment.

Lenalidomide-Induced Cytopenias: Relationship to Hematologic Improvement in Patients with Myelodysplastic Syndromes (MDS).

Long Term Clinical Benefit of Lenalidomide (Revlimid) Treatment in Patients with Myelodysplastic Syndrome without Del 5q Cytogenetic Abnormalities.

Long-Term Clinical Benefit of Lenalidomide (Revlimid) Treatment in Patients with Myelodysplastic Syndrome and Chromosome Deletion 5q.

A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only